ABL Diagnostics wins court approval to buy TEXCELL operations

ABL Diagnostics was selected by the Évry Commercial Court to acquire TEXCELL’s assets and business operations, a move that expands the company’s footprint in virology, biosafety and infectious disease work at Genopole in Évry-Courcouronnes. The deal includes 29 employees, continued customer contracts and an estimated €2.9 million economic value, with funding coming from ABL Diagnostics’ own resources.

Why it matters: - The acquisition gives ABL Diagnostics a stronger position in virology, biosafety and biological control, while adding operational presence at Genopole Évry-Courcouronnes. - The deal is designed to preserve scientific expertise and business continuity at TEXCELL while creating overlaps with ABL Diagnostics’ molecular diagnostics, infectious disease and software businesses. - The transaction also deepens ABL Diagnostics’ strategic ties to the Institut Pasteur ecosystem.

What happened: - The Évry Commercial Court selected ABL Diagnostics to acquire TEXCELL’s assets and business operations. - The court decision follows an industrial plan from ABL Diagnostics focused on continuity, preserving expertise and building synergies with its existing activities. - The acquisition covers TEXCELL’s strategic assets and operations, with commercial contracts transferred as part of the sale. - Operations will continue at the Genopole site in Évry-Courcouronnes. - The transaction transfers 29 employees, including 23 permanent staff and 6 apprentices or trainees. - ABL Diagnostics will assume accrued employee rights tied to the transferred staff, valued at €91,829.24, subject to final adjustment.

The details: - TEXCELL originated in the scientific ecosystem of Institut Pasteur and specializes in viral safety, biosafety, genomic analysis, immunological monitoring and services for biotechnology and innovative therapies. - Publicly available information shows TEXCELL France generated about €5.4 million in revenue in 2024, down from €6.2 million in 2023 and €7.5 million in 2022. - The overall economic value of the project is estimated at about €2.9 million. - That total includes a €225,000 purchase price for assets, split between €165,000 of intangible assets and €60,000 of tangible assets. - The deal also includes €30,000 excluding VAT for inventories. - ABL Diagnostics will reconstitute security deposits of about €100,000. - The company will assume lease-financing agreements for operational equipment, including future lease instalments of €531,792.74, subject to final adjustment. - ABL Diagnostics plans an industrial and technological investment program estimated at €930,000. - The company also estimates a €1 million increase in working capital needs to support the acquired activities. - ABL Diagnostics says the transaction is financed from the group’s available financial resources. - The terms of the accepted offer are set out in documents filed with the Évry Commercial Court. - TEXCELL’s expertise in viral safety, biological control, cell culture, viral characterization and biosafety complements ABL Diagnostics’ UltraGene, DeepChek® and Nadis® platforms. - The company plans to recruit about five additional employees to support scientific activities from TEXCELL. - ABL Diagnostics intends to keep developing the acquired assets, including characterized virus banks, cell line collections, virology expertise and biosafety infrastructure.

Between the lines: - The deal reinforces ABL Diagnostics’ push beyond core diagnostics into adjacent life sciences services where scientific know-how and regulated testing capabilities matter. - The acquisition also appears to preserve an existing specialist platform rather than rebuild the business from scratch, which can speed integration if the legal and operational handoff goes smoothly. - Management is signaling that the move fits a broader growth plan built on internal innovation plus targeted acquisitions. - ABL Diagnostics has already been working on an HPV RNA-Seq genotyping project with Institut Pasteur in Paris, and the TEXCELL purchase extends that strategic continuity. - The company’s comments suggest it sees automation, infrastructure upgrades and team growth as the next steps to scale the combined platform.

What’s next: - ABL Diagnostics said it will provide more information after the required legal and administrative formalities are completed. - The company plans to explain how the acquired activities will be integrated into its strategic roadmap and 2026 objectives. - ABL Diagnostics expects to invest in automation, infrastructure modernization, team expansion and scientific development to support labs, research centers, biotech companies and healthcare industry players worldwide. - The release includes forward-looking statements that remain subject to legal, regulatory and third-party approval risks.